Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas. Show more

Location: 3060 Pegasus Park Drive, Dallas, TX, 75247, United States | Website: https://www.fortebiorx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

128.9M

52 Wk Range

$4.11 - $28.68

Previous Close

$10.55

Open

$10.43

Volume

63,093

Day Range

$9.70 - $10.86

Enterprise Value

39.27M

Cash

45.86M

Avg Qtr Burn

-8.608M

Insider Ownership

9.35%

Institutional Own.

80.32%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
FB102 Details Celiac Disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FB102 Details Graft-versus-host disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.